Related Experiment Video
Updated: Jan 11, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
41.4K
Advances in Inhaled Nanoparticle Drug Delivery for Pulmonary Disease Management
Yunzhou Fan1, Yuefang Zhou1, Jing Zhao1
1Department of Physiology and Cell Biology, College of Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA.
Summary
Inhaled nanoparticle drug delivery systems offer a promising approach for treating lung diseases by targeting therapies directly to the lungs. These systems enhance drug distribution and retention, improving treatment efficacy while reducing side effects.
Area of Science:
- Biomedical nanotechnology
- Pulmonary medicine
- Drug delivery systems
Background:
- Pulmonary disorders, including COVID-19, present significant public health challenges with limited therapeutic options.
- Effective lung-targeted therapies require strategies that maximize local efficacy and minimize systemic toxicity.
Purpose of the Study:
- To review recent advances in inhaled nanoparticle drug delivery systems (INDDs) for lung diseases.
- To highlight design strategies for overcoming lung barriers and improving therapeutic efficacy.
Main Methods:
- Focus on critical carrier materials in INDD formulation.
- Evaluation of INDD performance in in vitro and in vivo studies.
- Analysis of inhalation dosage forms and delivery strategies.
Main Results:
- INDDs demonstrate capability in penetrating mucus and pulmonary surfactant barriers.
- Enhanced lung distribution, retention, and precise delivery of therapeutics to lung cells and lesions.
- INDDs serve as a universal translational platform for various respiratory disorders.
Conclusions:
- INDDs represent a powerful platform for targeted lung therapy.
- Optimizing INDD design is crucial for overcoming lung barriers and enhancing clinical and preclinical efficacy.
- This approach holds promise for a wide array of respiratory diseases.
Related Concept Videos
01:23Inhaled Medications
717
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
717
01:22Drug Delivery: Miscellaneous Routes
699
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
699
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
01:18Additional Routes of Drug Administration
4.6K
Choosing the appropriate route of drug administration is significantly influenced by two key factors: the therapeutic objectives and the inherent properties of the drug being used.
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
4.6K
01:26COPD: Management Using Bronchodilators and Corticosteroids
709
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
709